Evidence map›Paper›PMID 29537936›Full record

ArticlemAbs2018

Isolation and characterization of a monoclonal antibody containing an extra heavy-light chain Fab arm.

Dan Boyd, Arpa Ebrahimi, Sarah Ronan, Brian Mickus, Matthew Schenauer, Jenny Wang, Darren Brown, Alexandre Ambrogelly

Open access · goldAbstract read
In one paragraph

Article in mAbs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Label-free methods for opticalPhysical chemistry chemical physics : PCCP · 2021
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Dan Boyda Pharmaceutical & Biologics Development , Gilead Sciences , Oceanside , California , United States.
Arpa Ebrahimia Pharmaceutical & Biologics Development , Gilead Sciences , Oceanside , California , United States.
Sarah Ronana Pharmaceutical & Biologics Development , Gilead Sciences , Oceanside , California , United States.
Brian Mickusa Pharmaceutical & Biologics Development , Gilead Sciences , Oceanside , California , United States.
Matthew Schenauera Pharmaceutical & Biologics Development , Gilead Sciences , Oceanside , California , United States.
Jenny Wanga Pharmaceutical & Biologics Development , Gilead Sciences , Oceanside , California , United States.
Darren Browna Pharmaceutical & Biologics Development , Gilead Sciences , Oceanside , California , United States.
Alexandre Ambrogellya Pharmaceutical & Biologics Development , Gilead Sciences , Oceanside , California , United States.
Gilead Sciences (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isolation and characterization of monoclonal antibody (mAb) variants to understand the impact of their structure on function is a typical activity during early-stage candidate selection that contributes to derisking clinical development. In particular, efforts are devoted to characterizing oligomeric variants, owing to their potential immunogenic nature. We report here a mAb variant consisting of a canonical mAb monomer associated in a non-covalent fashion with an antigen-binding fragment (Fab) arm amputated from its Fc domain. The truncated heavy chain is encoded in the cell line genome and is the likely product of a genomic recombination during cell line generation. The addition of the Fab arm results in severe loss of potency, indicating its interaction with the Fab domain of the monomer. The presence of such a variant can easily be mitigated by an adequate purification step.

Indexed as

Antibodies, Monoclonal, HumanizedImmunoglobulin Heavy ChainsHumansImmunoglobulin Fab FragmentsImmunoglobulin GAntibodies, Monoclonal, HumanizedImmunoglobulin Fab FragmentsImmunoglobulin GImmunoglobulin Heavy Chainsantibody impuritiescell linehigh molecular weight speciesmAbmolecular size variantmonoclonal antibodySEC-MALSsize exclusion chromatography

Identifiers

PMID29537936
PMCPMC5916558
OpenAlexW2793369317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.